Trial Profile
A RANDOMIZED, MULTICENTER, LONG TERM STUDY OF THE SAFETY OF TANEZUMAB IN PATIENTS WITH CHRONIC LOW BACK PAIN
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary) ; Tanezumab (Primary)
- Indications Back pain
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Pfizer
- 11 May 2013 Results from an extension trial presented at the 32nd Annual Scientific Meeting of the American Pain Society.
- 23 Dec 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 19 Jul 2010 Status changed from recruiting to suspended, based on a Pfizer media release. Adverse events were noted tanezumab recipients with osteoarthritis, and the FDA requested suspension based on the potential for adverse events in other patient populations.